Beyond chemotherapy and targeted therapy: adoptive cellular therapy in non-small cell lung cancer |
| |
Authors: | Junying Wang Xueju Wang |
| |
Affiliation: | 1. Department of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun, 130021, Jilin, People’s Republic of China 2. Department of Pathology, The Third Hospital of Jilin University, Changchun, 130033, Jilin, People’s Republic of China
|
| |
Abstract: | Non-small cell lung cancer (NSCLC) is an intractable disease for which effective treatment approaches are urgently needed. The ability to induce antigen-specific immune responses in patients with lung cancer has led to the development of immunotherapy as a novel concept for the treatment of NSCLC. Adoptive cellular therapy (ACT) represents an important advancement in cancer immunotherapy with the utilization of tumor infiltrating lymphocytes, cytokine-induced killer cells, natural killer cells and γδ T cells. In this study, we review recent advances in ACT for NSCLC in clinical trials and provide a perspective on the improvement in ACT and potential therapeutic approaches using engineered T cell therapy for NSCLC. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|